CompletedPhase 2

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

France93 participantsStarted 2010-03

Plain-language summary

The primary objective of this study is to demonstrate the efficacy of T1225 eye drops versus placebo eye drops on the global ocular discomfort (VAS).

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓Diagnosis of moderate to severe chronic blepharitis (posterior and/or anterior) in at least one eligible eye

Visual Analogue Scale (VAS - Ranges 0-100 mm)

Timeframe: Baseline and D63 (D63 minus baseline)

NCT IDNCT01089608

SponsorLaboratoires Thea

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-06

Results submitted2014-10-07